Psychiatric side effects and fluctuations in serotonergic parameters in the treatment of chronic hepatitis C infection

Neuropsychobiology

Volumn 65, Issue 3, 2012, Pages 126-132

  Bezemer, G ^a   Van Gool, A R ^a,b   Fekkes, D ^a   Vrolijk, J M ^a   Hansen, B E ^a   Janssen, H L A ^a   De Knegt, R J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Yulius Mental Health Organization   (Netherlands)

Author keywords

Anger; Depression; Hepatitis C; Peginterferon; Tryptophan

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; AMINO ACID; BIOPTERIN; DOPAMINE; NEOPTERIN; NORADRENALIN; PEGINTERFERON ALPHA2A; PHENYLALANINE; PROLACTIN; RIBAVIRIN; SEROTONIN; TRYPTOPHAN; TYROSINE;

ADULT; ANGER; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DEPRESSION; DOPAMINE METABOLISM; FATIGUE; FEMALE; HEPATITIS C; HUMAN; MALE; MENTAL DISEASE; PRIORITY JOURNAL; PROFILE OF MOOD STATES; PSYCHOMETRY; SCORING SYSTEM; SEROTONIN METABOLISM; SEROTONINERGIC SYSTEM; TREATMENT OUTCOME; VIRUS HEPATITIS;

ADULT; ANTIVIRAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MOOD DISORDERS; NEOPTERIN; PHENYLALANINE; POLYETHYLENE GLYCOLS; PROLACTIN; PSYCHOMETRICS; RECOMBINANT PROTEINS; SEROTONIN; STATISTICS, NONPARAMETRIC; TIME FACTORS; TYROSINE;

EID: 84857461556     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000330585     Document Type: Article

References (27)

1. Lauer GM, Walker BD: Hepatitis C virus infection. New Engl J Med 2001; 345: 41-52. (Pubitemid 32634271)
2. Veldt BJ, Heathcote EJ, Wedemeyer H, et al: Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-684. (Pubitemid 351664462)
3. Imazeki F, Yokosuka O, Fukai K, Saisho H: Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 2003; 38: 493-502. (Pubitemid 36919871)
4. Van Gool AR, Kruit WH, Engels FK, Stoter G, Bannink M, Eggermont AM: Neuropsychiatric side effects of interferon-alfa therapy. Pharm World Sci 2003; 25: 11-20. (Pubitemid 36313885)
5. Schiepers OJ, Wichers MC, Maes M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 201-217. (Pubitemid 40202906)
6. Bonaccorso S, Marino V, Puzella A, et al: Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22: 86-90. (Pubitemid 34101297)
7. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R: Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002; 7: 468-473. (Pubitemid 34712898)
8. Van Gool AR, Fekkes D, Kruit WH, et al: Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients. Psychiatry Res 2003; 119: 125-132. (Pubitemid 36829424)
9. Russo S, Kema IP, Haagsma EB, et al: Irritability rather than depression during interferon treatment is linked to increased tryptophan catabolism. Psychosom Medicine 2005; 67: 773-777. (Pubitemid 41396025)
10. Michaelis M, Michaelis R, Suhan T, et al: Ribavirin inhibits angiogenesis by tetrahydrobiopterin depletion. Faseb J 2007; 21: 81-87. (Pubitemid 46052547)
11. Anderson DN, Wilkinson AM, Abou-Saleh MT, Blair JA: Recovery from depression after electroconvulsive therapy is accompanied by evidence of increased tetrahydrobiopterindependent hydroxylation. Acta Psychiatr Scand 1994; 90: 10-13. (Pubitemid 24212166)
12. Hoekstra R, van den Broek WW, Fekkes D, Bruijn JA, Mulder PG, Pepplinkhuizen L: Effect of electroconvulsive therapy on biopterin and large neutral amino acids in severe, medication-resistant depression. Psychiatry Research 2001; 103: 115-123. (Pubitemid 32817073)
13. Myint AM, Kim YK: Cytokine-serotonin interaction through IDO: A neurodegeneration hypothesis of depression. Medical Hypotheses 2003; 61: 519-525. (Pubitemid 37411894)
14. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M: IDO and interferonalpha-induced depressive symptoms: A shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005; 10: 538-544. (Pubitemid 40897037)
15. Zeuzem S, Pawlotsky JM, Lukasiewicz E, et al: International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005; 43: 250-257. (Pubitemid 40956877)
16. Fekkes D, van Dalen A, Edelman M, Voskuilen A: Validation of the determination of amino acids in plasma by high-performance liquid chromatography using automated pre-column derivatization with o-phthaldialdehyde. J Chromatogr B Biomed Appl 1995; 669: 177-186.
17. Fukushima T, Nixon JC: Analysis of reduced forms of biopterin in biological tissues and fluids. Anal Biochem 1980; 102: 176-188. (Pubitemid 10099498)
18. Borgdorff P, Fekkes D, Tangelder GJ: Hypotension caused by extracorporeal circulation: Serotonin from pump-activated platelets triggers nitric oxide release. Circulation 2002; 106: 2588-2593. (Pubitemid 35340696)
19. Cozzi A, Zignego AL, Carpendo R, et al: Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients. J Viral Hepat 2006; 13: 402-408. (Pubitemid 44030262)
20. Bannink M, Fekkes D, Van Gool AR, et al: Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects. Neuropsychobiology 2007; 55: 225-231. (Pubitemid 47525244)
21. Van Gool AR, van Ojik HH, Kruit WH, et al: Pegylated interferon-alpha2b treatment in melanoma patients: Influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations. Anticancer Drugs 2004; 15: 587-591. (Pubitemid 38932326)
22. Plockinger U, Kruger D, Bergk A, Weich V, Wiedenmann B, Berg T: Hepatitis-C patients have reduced growth hormone (GH) secretion which improves during long-term therapy with pegylated interferon-alpha. Am J Gastroenterol 2007; 102: 2724-2731. (Pubitemid 350179318)
23. Kraus MR, Schafer A, Bentink T, et al: Sexual dysfunction in males with chronic hepatitis C and antiviral therapy: Interferon-induced functional androgen deficiency or depression? J Endocrinol 2005; 185: 345-352. (Pubitemid 40691799)
24. Durazzo M, Premoli A, Di Bisceglie C, et al: Alterations of seminal and hormonal parameters: An extrahepatic manifestation of HCV infection? World J Gastroenterol 2006; 12: 3073-3076. (Pubitemid 43811087)
25. Reuwer AQ, van Zaane B, van Wissen M, van Zanten AP, Twickler MT, Gerdes VE: Prolactin is involved in the systemic inflammatory response in myocardial infarction. Horm Metab Res 2011; 43: 62-65.
26. El-Serag HB, Kunik B, Richardson P, Rabeneck L: Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002; 123: 476-482. (Pubitemid 34827192)
27. Wilson MP, Castillo EM, Batey AM, Sapyta J, Aronson S: Hepatitis C and depressive symptoms: Psychological and social factors matter more than liver injury. Int J Psychiatry Med 2010; 40: 199-215.